Multimodal nanoparticles that provide immunomodulation and intracellular drug delivery for infectious diseases

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 4, 2014, Pages 831-838

  Dube, Admire ^a,e   Reynolds, Jessica L ^b   Law, Wing Cheung ^c   Maponga, Charles C ^a   Prasad, Paras N ^c,d   Morse, Gene D ^c  

^a UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d Korea University   (South Korea)

^e Future production Chemicals Cluster   (South Africa)

Author keywords

1,3 glucan; Infectious diseases; Multimodal nanoparticles; Mycobacterium tuberculosis; PLGA

Indexed keywords

CHITOSAN; DRUG DELIVERY; ENZYME ACTIVITY; IMMUNE SYSTEM; LIGANDS; MACROPHAGES; NITROGEN; OXYGEN; PHYSIOLOGY;

HOST IMMUNE RESPONSE; INFECTIOUS DISEASE; INTRACELLULAR DRUG DELIVERY; MULTI-MODAL NANOPARTICLES; MYCOBACTERIUM TUBERCULOSIS; PLGA; PRO-INFLAMMATORY CYTOKINES; REACTIVE OXYGEN AND NITROGEN SPECIES;

NANOPARTICLES;

BETA 1,3 GLUCAN; CHITOSAN; DECTIN 1; GAMMA INTERFERON; INTERLEUKIN 12P70; MULTIMODAL NANOPARTICLE; NANOPARTICLE; NITROGEN DERIVATIVE; POLY(LACTIDE)CO GLYCOLIDE; REACTIVE OXYGEN METABOLITE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; IMMUNOLOGIC FACTOR; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INFECTION; MACROPHAGE; CHEMISTRY; FEMALE; IMMUNOLOGY; MALE; MONOCYTE; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES; TUBERCULOSIS;

CHITOSAN; CYTOKINES; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LACTIC ACID; MALE; MONOCYTES; MYCOBACTERIUM TUBERCULOSIS; NANOPARTICLES; POLYGLYCOLIC ACID; TUBERCULOSIS;

EID: 84900317298     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.11.012     Document Type: Article

References (26)

1. World Health Organization Malaria Fact Sheet No. 94 Available From:, Accessed 23 October 2013. http://Www.Who.Int/Mediacentre/Factsheets/Fs094/En/Index.Html.
2. World Health Organization Tuberculosis Fact Sheet No. 104-Global And Regional Incidence Available From:, Accessed 23 October 2013. http://Www.Who.Int/Mediacentre/Factsheets/Fs104/En/.
3. World Health Organization HIV/AIDS Fact Sheet No. 360 Available From, Accessed 23 October 2013. http://Www.Who.Int/Mediacentre/Factsheets/Fs360/En/Index.Html.
4. Prasad P.N. Introduction to Nanomedicine and nanobioengineering 2012, 393-430. New Jersey, Wiley. K. Chang (Ed.).
5. Hayeshi R., Semete B., Kalombo L., Katata L., Lemmer Y., Melariri P., et al. Nanomedicine in the development of drugs for poverty-related diseases. Drug Discovery In Africa 2012, 407-429. Berlin, Springer.
6. Kanki P. Infectious diseases, introduction. Infectious diseases 2013, 1-6. New York, Springer. P. Kanki, D.J. Grimes (Eds.).
7. Giacomini E., Iona E., Ferroni L., Miettinen M., Fattorini L., Orefici G., et al. Infection of human macrophages and dendritic cells with mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response. J Immunol 2001, 166(12):7033-7041.
8. Gupta D., Sharma S., Singhal J., Satsangi A.T., Antony C., Natarajan K. Suppression of TLR2-induced IL-12, reactive oxygen species, and inducible nitric oxide synthase expression by mycobacterium tuberculosis antigens expressed inside macrophages during the course of infection. J Immunol 2010, 184(10):5444-5455.
9. Schluger N.W., Rom W.N. The host immune response to tuberculosis. Am J Respir Crit Care Med 1998, 157(3):679-691.
10. Ahmad S. Pathogenesis, immunology, and diagnosis of latent mycobacterium tuberculosis infection. Clin Dev Immunol 2011, [17 pages].
11. Multifunctional nanoparticles for drug delivery applications: imaging, targeting, and delivery 2012, New York, Springer. S. Svenson, R.K. Prud'homme (Eds.).
12. Goodridge H.S., Wolf A.J., Underhill D.M. Β-glucan recognition by the innate immune system. Immunol Rev 2009, 230(1):38-50.
13. Chan G.C., Chan W.K., Sze D.M. The effects of beta-glucan on human immune and cancer cells. J Hematol Oncol 2009, 2:25.
14. Winkler A.R., Nocka K.H., Sulahian T.H., Kobzik L., Williams C.M.M. In vitro modeling of human alveolar macrophage smoke exposure: enhanced inflammation and impaired function. Exp Lung Res 2008, 34(9):599-629.
15. Kumar M.N.V.R., Bakowsky U., Lehr C.M. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 2004, 25(10):1771-1777.
16. Tiwari B.M., Kannan N., Vemu L., Raghunand T.R. The mycobacterium tuberculosis PE proteins Rv0285 and Rv1386 modulate innate immunity and mediate bacillary survival in macrophages. Plos One 2012, 7(12). E51686.
17. Sada-Ovalle I., Chavez-Galan L., Torre-Bouscoulet L., Nava-Gamino L., Barrera L., Jayaraman P., et al. The Tim3-galectin 9 pathway induces antibacterial activity in human macrophages infected with mycobacterium tuberculosis. J Immunol 2012, 189(12):5896-5902.
18. Xu S., Huo J., Lee K.-G., Kurosaki T., Lam K.-P. Phospholipase Cγ2 is critical for dectin-1-mediated Ca2+ flux and cytokine production in dendritic cells. J Biol Chem 2009, 284(11):7038-7046.
19. Kusner D.J. Mechanisms of mycobacterial persistence in tuberculosis. Clin Immunol 2005, 114(3):239-247.
20. Brown G.D., Gordon S. Immune recognition. A New receptor for beta-glucans. Nature 2001, 413(6851):36-37.
21. Hetland G., Sandven P. Β-1,3-glucan reduces growth of mycobacterium tuberculosis in macrophage cultures. FEMS Immunol Med Microbiol 2002, 33(1):41-45.
22. Reljic R., Paul M.J., Arias M.A. Cytokine therapy of tuberculosis at the crossroads. Expert Rev Respir Med 2009, 3(1):53-66.
23. Cooper A.M., Mayer-Barber K.D., Sher A. Role of innate cytokines in mycobacterial infection. Mucosal Immunol 2011, 4(3):252-260.
24. Cooper A.M., Khader S.A. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev 2008, 226:191-204.
25. Grosset J., Almeida D., Converse P.J., Tyagi S., Li S.-Y., Ammerman N.C., et al. Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proc Natl Acad Sci 2012, 109(37):15001-15005.
26. Gumbo T., Louie A., Deziel M.R., Liu W., Parsons L.M., Salfinger M., et al. Concentration-dependent mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007, 51(11):3781-3788.